{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:31:10Z","timestamp":1749493870133,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Pharmaceuticals Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Early intervention to reduce the impact of adverse events (AEs) may improve patients\u2019 quality of life and enable optimal treatment duration.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This nationwide, multicenter, prospective, longitudinal, 1-year observational study investigated patients\u2019 self-management of AEs associated with targeted therapy for advanced renal cell carcinoma (RCC) and explored corresponding outcomes, including treatment duration and patient-reported outcomes (PROs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 77 advanced RCC patients (mean age 62\u00a0years) treated with a first targeted therapy. 210 cases of seven AEs of interest (fatigue, hand-foot syndrome, oral mucosal inflammation, diarrhea, gastrointestinal symptoms, hypertension, and anorexia) were observed. Most AEs were mild to moderate. Overall, 63.4% of patients were identified as managing their AEs well, reporting numerically longer treatment duration and significantly higher PRO scores than patients identified as poor managers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Longer treatment duration and improved PROs were observed when advanced RCC patients managed targeted therapy-associated AEs well. Repeated education for consolidating AE self-management could be considered to enhance overall treatment outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-022-00532-0","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T13:22:45Z","timestamp":1671196965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patients\u2019 self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study"],"prefix":"10.1186","volume":"6","author":[{"given":"Sung-Hoo","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Seok","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ill-Young","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Gyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Il","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Koo","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juneyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2251-5331","authenticated-orcid":false,"given":"Jinsoo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"11","key":"532_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.6004\/jnccn.2019.0054","volume":"17","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, Hammond LJ, Zuccarino-Catania G (2019) NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw 17(11):1278\u20131285. https:\/\/doi.org\/10.6004\/jnccn.2019.0054","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"532_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12032-014-0190-6","volume":"31","author":"H Miyake","year":"2014","unstructured":"Miyake H, Harada K, Inoue TA, Fujisawa M (2014) Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors. Med Oncol 31(9):190. https:\/\/doi.org\/10.1007\/s12032-014-0190-6","journal-title":"Med Oncol"},{"issue":"Suppl 1","key":"532_CR3","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1007\/s10555-012-9355-y","volume":"31","author":"MJ M\u00e9ndez-Vidal","year":"2012","unstructured":"M\u00e9ndez-Vidal MJ, Mart\u00ednez Ortega E, Montesa Pino A, P\u00e9rez Valderrama B, Viciana R (2012) Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31(Suppl 1):S19\u2013S27. https:\/\/doi.org\/10.1007\/s10555-012-9355-y","journal-title":"Cancer Metastasis Rev"},{"issue":"6_suppl","key":"532_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/jco.2013.31.6_suppl.445","volume":"31","author":"B Eberhardt-Wetherington","year":"2013","unstructured":"Eberhardt-Wetherington B, Gall V, Lang M, Schmidinger M, Gruenwald V, Claussen C, Wartenberg M, Niedtner R, Kalanovic D (2013) Patient and physician perspective on published therapy management recommendations for TKI-treated patients with a focus on sunitinib: The TheMaPaC project (Therapy Management Patient Consensus). J Clin Oncol 31(6_suppl):445","journal-title":"J Clin Oncol"},{"issue":"2","key":"532_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s12032-011-9922-z","volume":"29","author":"BA Feinberg","year":"2012","unstructured":"Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS (2012) Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 29(2):786\u2013794. https:\/\/doi.org\/10.1007\/s12032-011-9922-z","journal-title":"Med Oncol"},{"key":"532_CR6","volume-title":"Design and Analysis of Clinical Trials: Concepts and Methodologies","author":"SC Chow","year":"2004","unstructured":"Chow SC, Liu JP (2004) Design and Analysis of Clinical Trials: Concepts and Methodologies. Wiley, New York"},{"key":"532_CR7","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40"},{"issue":"10","key":"532_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"issue":"7","key":"532_CR9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s11136-015-1205-210","volume":"25","author":"SH Kim","year":"2016","unstructured":"Kim SH, Ahn J, Ock M, Shin S, Park J, Luo N, Jo MW (2016) The EQ-5D-5L valuation study in Korea. Qual Life Res 25(7):1845\u20131852. https:\/\/doi.org\/10.1007\/s11136-015-1205-210","journal-title":"Qual Life Res"},{"issue":"3","key":"532_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF00433915","volume":"5","author":"AE Bonomi","year":"1996","unstructured":"Bonomi AE, Cella DF, Hahn EA, Bjordal K, Sperner-Unterweger B, Gangeri L, Bergman B, Willems-Groot J, Hanquet P, Zittoun R (1996) Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5(3):309\u2013320. https:\/\/doi.org\/10.1007\/BF00433915","journal-title":"Qual Life Res"},{"issue":"2","key":"532_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0163278705275342","volume":"28","author":"SL Eremenco","year":"2005","unstructured":"Eremenco SL, Cella D, Arnold BJ (2005) A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 28(2):212\u2013232. https:\/\/doi.org\/10.1177\/0163278705275342","journal-title":"Eval Health Prof"},{"issue":"2","key":"532_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","volume":"8","author":"D Wild","year":"2005","unstructured":"Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P, ISPOR Task Force for Translation and Cultural Adaptation (2005) Principles of good practice for the translation and cultural adaptation process for patient reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 8(2):94\u2013104. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.04054.x","journal-title":"Value Health"},{"issue":"4","key":"532_CR13","first-page":"191","volume":"4","author":"D Cella","year":"2006","unstructured":"Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K, George J, Bro WP, Kelly C, Bukowski R (2006) Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI). J Support Oncol 4(4):191\u2013199","journal-title":"J Support Oncol"},{"issue":"5","key":"532_CR14","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/aje\/kwx311","volume":"187","author":"RH Keogh","year":"2018","unstructured":"Keogh RH, Daniel RM, VanderWeele TJ, Vansteelandt S (2018) Analysis of longitudinal studies with repeated outcome measures: adjusting for time-dependent confounding using conventional methods. Am J Epidemiol 187(5):1085\u20131092. https:\/\/doi.org\/10.1093\/aje\/kwx311","journal-title":"Am J Epidemiol"},{"issue":"8","key":"532_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722\u2013731. https:\/\/doi.org\/10.1056\/NEJMoa1303989","journal-title":"N Engl J Med"},{"issue":"8","key":"532_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/1078155217719583","volume":"24","author":"S Srinivas","year":"2018","unstructured":"Srinivas S, Stein D, Teltsch DY, Tao S, Cisar L, Ramaswamy K (2018) Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma. J Oncol Pharm Pract 24(8):574\u2013583. https:\/\/doi.org\/10.1177\/1078155217719583","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"532_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/djr511","volume":"104","author":"T Eisen","year":"2012","unstructured":"Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104(2):93\u2013113. https:\/\/doi.org\/10.1093\/jnci\/djr511","journal-title":"J Natl Cancer Inst"},{"issue":"2 Suppl","key":"532_CR18","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.5489\/cuaj.67","volume":"1","author":"C Kollmannsberger","year":"2007","unstructured":"Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1(2 Suppl):S41\u2013S54. https:\/\/doi.org\/10.5489\/cuaj.67","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"532_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/cam4.302","volume":"3","author":"C Porta","year":"2014","unstructured":"Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS (2014) Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med 3(6):1517\u20131526. https:\/\/doi.org\/10.1002\/cam4.302","journal-title":"Cancer Med"},{"issue":"1","key":"532_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11136-017-1704-4","volume":"27","author":"S de Groot","year":"2018","unstructured":"de Groot S, Redekop WK, Versteegh MM, Sleijfer S, Oosterwijk E, Kiemeney LALM, Uyl-de Groot CA (2018) Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res 27(1):115\u2013124. https:\/\/doi.org\/10.1007\/s11136-017-1704-4","journal-title":"Qual Life Res"},{"issue":"3","key":"532_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","volume":"48","author":"D Cella","year":"2012","unstructured":"Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN (2012) Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer 48(3):311\u2013323. https:\/\/doi.org\/10.1016\/j.ejca.2011.05.017","journal-title":"Eur J Cancer"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-022-00532-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T13:32:22Z","timestamp":1671197542000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-022-00532-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1186\/s41687-022-00532-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"type":"electronic","value":"2509-8020"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board at each participating center approved this study. Only patients who had read and signed the written consent forms before study participation were enrolled.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Young-Joo Kim, Sang-Hee Kim and Jee-Sun Lee are employees of Pfizer Pharmaceuticals Korea Ltd. We declare that the other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}